Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time, cell‑free DNA has already reached clinical use, where it is increasingly adopted to treat patients and now operates alongside plasmid DNA within today’s manufacturing landscape. How can companies optimize and select the right DNA technology to meet evolving demands for scale, consistency, speed, and cost of goods?

Download the webinar to watch as two leading DNA experts have a candid debate with real-world data exploring where plasmid DNA continues to excel, where cell-free DNA is uniquely positioned, and how both platforms will shape the future of the cell and gene therapy landscape.